LumiThera Acquires Diopsys
November 11, 2021
LumiThera, a commercial-stage ophthalmic medical device company, entered a definitive merger agreement to acquire Diopsys in a stock-for-stock transaction under which Diopsys will become a wholly owned subsidiary of LumiThera. The deal combines Diopsys' visual electrophysiology diagnostic systems with LumiThera's photobiomodulation treatment platform to create a coordinated light-based theranostic approach for diagnosing, treating and monitoring ocular disease.
- Buyers
- LumiThera, Inc.
- Targets
- Diopsys, Inc.
- Sellers
- Diopsys stockholders
- Industry
- Medical Devices
- Location
- Pennsylvania, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Alcon to Acquire LumiThera
July 7, 2025
Medical Devices
Alcon, a leader in eye care, plans to acquire LumiThera, which develops light-based therapies for ophthalmology, including its photobiomodulation (PBM) device for treating early and intermediate dry age-related macular degeneration (AMD). The acquisition is expected to close in the third quarter of 2025, subject to customary closing conditions and a LumiThera shareholder vote.
-
LumiThera Acquires MacuLogix Assets (AdaptDx Pro)
July 26, 2022
Medical Devices
LumiThera, through a wholly owned subsidiary, purchased the assets of MacuLogix, including the AdaptDx Pro dark adaptometer used for early diagnosis of dry age-related macular degeneration (AMD). The acquisition expands LumiThera's diagnostic and monitoring capabilities and complements its Valeda photobiomodulation treatment platform for dry AMD patients.
-
Caldera Medical Acquires UVision 360 and the LUMINELLE Product Family
October 8, 2024
Medical Devices
Caldera Medical has acquired UVision 360, the developer of the LUMINELLE hysteroscopy and cystoscopy systems, expanding its minimally invasive women's health device portfolio. The deal brings the LUMINELLE product family — including the new LUMINELLE Bx on-demand biopsy technology — into Caldera's commercial infrastructure to broaden office-based and surgical hysteroscopy capabilities.
-
DiscernDx Acquires Luminist Labs
April 29, 2020
Biotechnology
DiscernDx, a Palo Alto precision medicine company, has acquired Luminist Labs, a privately-held diagnostic platform developer focused on early detection and diagnosis of liver disease. The acquisition will integrate Luminist's data and platform into DiscernDx's multi-omics system to accelerate development of non-invasive diagnostic and prognostic solutions for NASH and other chronic metabolic liver diseases. Terms were not disclosed.
-
Roche to Acquire LumiraDx Point-of-Care Technology Platform for $295 Million
January 2, 2024
Healthcare Services
LumiraDx has entered into a definitive agreement for Roche to acquire certain companies and related assets within LumiraDx’s point-of-care diagnostics platform business. Roche will pay $295 million at closing, with an additional payment of up to $55 million for reimbursement to fund the platform business until closing.
-
Boston Scientific Acquires Lumenis Surgical Business from Baring Private Equity Asia for $1.07B
March 3, 2021
Medical Devices
Boston Scientific has agreed to acquire the Lumenis Surgical Business from Baring Private Equity Asia/Lumenis for USD 1.07 billion, subject to closing adjustments. The deal transfers Lumenis' surgical laser portfolio and global surgical team (including its Israeli laser center of excellence) to Boston Scientific to bolster its Urology strategy, while Lumenis — still owned by BPEA — will focus on Aesthetics and Vision.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.